NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • A Guide to What We Do
    • Activities during COVID-19
    • Strategic Partnership Board
    • Steering Committee
    • Promoting Equality, Diversity and Inclusion in Research
    • Current Vacancies
    • Contact Us
    • Stay in Touch
  • Research
        • OUR 20 RESEARCH THEMES

        • Antimicrobial Resistance and Modernising Microbiology
        • Cardiovascular
        • Clinical Informatics and Big Data
        • Diabetes and Metabolism
        • Gastroenterology and Mucosal Immunity
        • Genomic Medicine
        • Haematology and Stem Cells
        • Imaging
        • Molecular Diagnostics
        • Multi-Modal Cancer Therapies
        • Multi-Morbidity and Long-Term Conditions
        • Musculoskeletal
        • Neurological Conditions
        • Obesity, Diet and Lifestyle
        • Partnerships for Health, Wealth and Innovation
        • Respiratory
        • Stroke and Vascular Dementia
        • Surgical Innovation and Evaluation
        • Technology and Digital Health
        • Vaccines for Emerging and Endemic Diseases
        • Oxford Biomedical Research Centre activities during COVID-19
  • Patient & Public Involvement
    • Getting involved with research
    • Researcher Guidance
    • Post an opportunity for patient and public involvement
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Preparatory Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • What Can We Do For Your Organisation?
    • Who Do We Work With?
    • IP and Licensing
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > COVID-19 > Serum iron may be useful biomarker to identify COVID-19 disease severity

Serum iron may be useful biomarker to identify COVID-19 disease severity

15 June 2020 · Listed under COVID-19, Haematology and Stem Cells

A new study led by University of Oxford researchers has found that patients with severe COVID-19 respiratory failure have very low levels of iron, compared to those with less severe disease. 

Changes in iron levels have been associated with worsening disease for other viral infections such as HIV and Hepatitis C, but this is the first study to find a similar link for COVID-19.

The investigations are part of a NIHR Oxford BRC-funded study evaluating blood cell-related biomarkers associated with adverse outcomes in COVID-19 infections.

Iron is essential for the growth of pathogens, but also for the body’s own immune response. So during an infection, the immune system ‘sequesters’ iron to deprive pathogens. At the same time, the immune system’s T and B lymphocytes (white blood cells that are a key art of the body’s immune response) need iron to clear the infection.

The researchers analysed blood samples collected from 30 critically ill COVID-19 patients when they were first admitted to the John Radcliffe Hospital in Oxford. The blood samples were collected within 24 to 48 hours of the patients being admitted.

Low iron levels also correlated with fewer lymphocytes, which are the major players in the body’s ‘adaptive’ immune response: unlike innate immunity, which identifies and reacts to general threats, the adaptive immune response tailor-makes antibodies for pathogens it has previously encountered. 

Other studies have also reported that low levels of T lymphocytes appear to correlate with more severe COVID-19 symptoms, so the correlation between low iron levels and lymphocyte numbers here suggests that iron may contribute to possible T-cell dysfunction too.

The study, published in the journal Critical Care, is part of an ongoing collaboration between ICU academic clinicians Dr Akshay Shah and Dr Stuart McKechnie, and Professor Hal Drakesmith’s research group at the MRC Wetherall Institute of Molecular Medicine (WIMM) at the John Radcliffe Hospital.

“It’s important to note that we don’t think that low levels of iron are causing worse COVID-19 disease,” says Dr Shah, the ICU doctor and researcher who is lead author on the study. “Instead, iron may be a signal picking up on other processes linked to disease severity.”

Professor Drakesmith said: “Low concentrations of iron in the bloodstream are commonly observed in infections but we were surprised indeed by the very low level in severely ill COVID-19 patients. We now need to investigate the causes and consequences of this phenomenon, and how it might contribute to the disease.”

← Study explores effects of COVID-19 on sleep
Breakthrough in RECOVERY COVID-19 drug treatment trial →

News

  • Lymph nodes reveal more about mechanisms of autoimmunity 14 June 2022
  • Conference aims to forge collaborations to tackle dementia 9 June 2022
  • Lung function device wins top chemistry Prize 8 June 2022
See full news archive

News Categories

Month Archives

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Oxford BRC on Social Media

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Feedback

We’d love to hear your feedback. Please contact us at obrcenquiries@ouh.nhs.uk

  • Sitemap
  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2022 NIHR Oxford Biomedical Research Centre